Salute e Benessere
GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight
Discover which indication is expected to grab the major GPRC5D-directed therapies market share @
The GPRC5D-directed therapies market is emerging as a significant focus within the landscape of multiple myeloma treatment. GPRC5D is an orphan receptor predominantly expressed on malignant plasma cells, with limited expression in normal tissues, making it an attractive therapeutic target. Its , allowing it to serve as a complementary or alternative target, particularly in patients who have relapsed after BCMA-directed treatments. This has driven a wave of innovation in .
The competitive landscape is rapidly evolving, with multiple biotech and pharmaceutical companies through preclinical and clinical pipelines. Notably, companies such as (via its teclistamab platform) are exploring GPRC5D-directed bispecifics and CAR-T constructs, respectively. Early-phase clinical trials have shown , even among those previously treated with BCMA-targeted agents. The ability of GPRC5D-targeting therapies to produce , with manageable toxicity profiles, is a key factor fueling investor interest and partnerships in this space.
Market dynamics are further shaped by the . As more patients receive BCMA therapies earlier in their treatment journeys, resistance and relapse rates have prompted the search for alternative targets like GPRC5D. , including the FDA and EMA, have shown for novel immunotherapies in RRMM, creating favorable conditions for GPRC5D-focused assets. Additionally, the is poised to enhance patient access and reduce logistical burdens compared to autologous CAR-T approaches.
However, challenges remain in this emerging space. will be crucial, as companies aim to optimize dosing schedules, minimize on-target off-tumor toxicities, and address manufacturing scalability. will also play a critical role, particularly as comes under scrutiny from payers and health systems.
Looking forward, the GPRC5D-directed therapy market is expected to expand significantly over the next 10 years, driven by a . Success in this domain will likely depend on the into combination regimens, leverage companion diagnostics to optimize patient selection, and establish long-term safety and efficacy through robust Phase III trials and real-world evidence.
GPRC5D is highly expressed in multiple myeloma cells and is found in abundance within the bone marrow of patients diagnosed with multiple myeloma or smoldering multiple myeloma. Currently, , approved in August 2023 , is the first and the only approved GPRC5D-directed therapy in the market. TALVEY is a novel, first-in-class bispecific T-cell engager that simultaneously binds to the CD3 receptor on T cells and GPRC5D, which is present on multiple myeloma cells, non-cancerous plasma cells, and certain healthy epithelial tissues, particularly in the skin and tongue. It is administered subcutaneously on a weekly or biweekly basis following an initial step-up dosing phase, giving physicians the flexibility to tailor dosing schedules to individual patient needs.
Learn more about the FDA-approved GPRC5D-directed therapies @
Some of the major emerging key players in the GPRC5D market include (CT071), (OriCAR-017), (Arlocabtagene autoleucel), (AZD0305), and others.
is an innovative CAR T cell therapy developed to target GPRC5D, aimed at treating relapsed or refractory multiple myeloma. Developed using Oricell Therapeutics' advanced proprietary technology, OriCAR-017 demonstrates unique advantages in terms of binding strength, cell persistence, tumor-fighting capability, and safety. It received Investigational New Drug (IND) approval from the U.S. FDA in January 2024 , following earlier approval by China's NMPA in 2023.
is an autologous CAR T cell therapy also directed at GPRC5D. Currently under evaluation in the Phase II QUINTESSENTIAL trial for relapsed/refractory multiple myeloma, the therapy is expected to yield key data in 2026. At the ASH 2023 conference, updated results from its Phase I trial highlighted durable responses, manageable safety, and clinical activity in patients regardless of prior BCMA-targeted treatment exposure.
The anticipated launch of these emerging therapies are poised to transform the GPRC5D-directed therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPRC5D-directed therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about GPRC5D-directed therapies clinical trials, visit @
GPRC5D, an orphan G-protein-coupled receptor located on chromosome 12p13, lacks a known ligand. It has emerged as a validated therapeutic target in multiple myeloma. Early-phase clinical trials involving T–cell–reducing therapies aimed at GPRC5D have demonstrated encouraging efficacy along with tolerable safety profiles, although these findings still require confirmation in Phase III studies.
This receptor is highly expressed in multiple myeloma cells and is prevalent in the bone marrow of patients with both active and smoldering disease. Furthermore, its mRNA levels are notably higher in multiple myeloma compared to other hematologic malignancies. The selective overexpression of GPRC5D in myeloma cells makes it an attractive candidate for immune effector cell–based therapies. Targeting GPRC5D, either as a standalone treatment or in combination with other anti-myeloma agents, could broaden the therapeutic landscape, particularly for patients who require novel mechanisms of action, whether to delay the use of BCMA-targeted therapies, overcome poor responses or antigen loss, or address clonal variability.
Although GPRC5D and BCMA are both expressed on CD138+ myeloma cells, their expression is not interdependent, making them distinct therapeutic targets. Importantly, GPRC5D expression remains stable even when BCMA is lost, a known resistance mechanism in some relapsed patients, supporting the rationale for combining GPRC5D- and BCMA-directed T-cell therapies to better manage the disease's heterogeneity.
The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Discover more about GPRC5D-directed therapies in development @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CAR-T companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bispecifics/trispecifics companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gprc5d-directed-therapies-market-is-anticipated-to-gain-momentum-during-the-forecast-period-20252034-owing-to-unmet-need-in-multiple-myeloma--delveinsight-302497463.html